SLC1A5 and glioma: Furthermore, SLC1A5, one of the FRGs in prognostic model, enhances the malignancy of gliomas, modulates the tumor ferroptosis status and immune microenvironment, and may be a potential prognostic biomarker and promising candidate target for glioma treatment.